EarGenie: Personalised management of hearing impairment for infants


Pictured: Bionics Institute CEO Robert Klupacs with Federal Minister for Health Hon. Greg Hunt MP at the launch of BioMedTech Horizons in April 2018.

EarGenie is an innovative system for personalised management of hearing impairment aiming to enable life-long benefits, using a novel combination of electrophysiology and functional near-infrared spectroscopy (fNIRS) to perform a diagnostic hearing evaluation. 

Deaf infants face delayed and inadequate language development, affecting education, social participation, and even employment later in life. Major contributing factors are the delay between diagnosis and the selection and accurate adjustment of hearing devices, delayed individualised optimisation of device features, and difficulty choosing a specific therapy to optimise language development. EarGenie is set to transform the precision of diagnosis and optimisation of hearing instrument function, to deliver major benefit to language development in deaf children. This project will allow for the development of a clinical prototype as well as plans for regulatory approval and clinical trials.

Visit Bionics Institute for more information.

Twitter: @BionicsInst

LinkedIn: Bionics Institute

Consortium Lead:Bionics Institute
Consortium Partners:Hydrix, Taralye Early Intervention Centre, Plunkett Consulting Group, Australian Hearing
Contact:Professor Colette McKay, Leader of Translational Hearing Research - cmckay@bionicsinstitute.org